Skip to main content

Closed

SPRY: ARS Pharmaceuticals, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+297063.3% / yr

Operating margin-204.5%

ROIC-85.0%

Financially safe

Stretched

Debt / equity1.57×

Interest coverage-82.9×

Current ratio4.94×

ARS Pharmaceuticals, Inc.

SPRYNASDAQ Global Market·USD·Closed

ARS Pharmaceuticals, Inc.

SPRYNASDAQ·USD·Closed

$5.13

−8.88%

$5.13

−$0.50 (8.88%)

52W Range

0thpctl

Volume

1.02×avg

Mkt Cap

509.43MUSD

P/E

-2.6TTM

Div Yield

–ann

52W Range

0thpctl

Volume

1.02×avg

Market Cap

509.43MUSD

P/E Ratio

-2.6TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings